Eucure Bio, a subsidiary of Beijing 's Biocytogen, will collaborate with San Diego 's Tracon Pharma to develop its CTLA-4 antibody for soft tissue sarcoma in North America . Eucure says YH001 has enhanced ADCC and CDC efficacy that differentiate the candidate from other CTLA-4 products. Tracon will be responsible for the clinical development and markteting of YH001 in multiple oncology indications in the US while Eucure Biopharma will supply YH001. Tracon will pay escalating double digit royalties on net sales to Eucure Biopharma. More details.... Stock Symbol: (NSDQ: TCON) Share this with colleagues: // //